ANGN discontinues all clinical development to preserve cash: https://www.globenewswire.com/news-release/2022/07/25/2485413/0/en/Angion-Announces-Process-to-Explore-Strategic-Alternatives-for-Enhancing-and-Preserving-Shareholder-Value.html AGN is now a shell company with approximately $60M in cash. See #msg-169278373 for related info.